Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MIRMthis companyMirum Pharmaceuticals, Inc.	$92.38	-168.06×	12.6×	7.61×	231.78×	-3770.3%	80.7%	-4.2%	-4.5%	-7.4%	-3.5%	1.4%	1.02×	1.32×	-1.54×	2.67×	0.0%	3	-0.33	2	C
AGIOAgios Pharmaceuticals, Inc.	$30.31	-3.82×	1.32×	29.21×	-3.74×	-87.2%	78.7%	-873.9%	-764.0%	-34.6%	-38.2%	-23.9%	0.03×	0.12×	0×	11.46×	0.0%	3	11.59	2	C
ALTAltimmune, Inc.	$2.20	-3.61×	1.41×	7,757.46×	-3.56×	-96.0%	100.0%	-230461.0%	-214861.0%	-39.2%	-35.4%	-21.2%	0.16×	0.09×	-57.76×	18.55×	0.0%	2	2.76	2	C+
ARCTArcturus Therapeutics Holdings Inc.	$10.42	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
ENTAEnanta Pharmaceuticals, Inc.	$11.46	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
MDGLMadrigal Pharmaceuticals, Inc.	$428.56	-45.32×	21.68×	13.63×	-49.99×	476.6%	94.1%	-31.3%	-30.1%	-47.8%	-31.6%	-1.5%	0.59×	-0.59×	-13.45×	4.01×	0.0%	2	6.8	2	C
Peer median	—	-3.61×	1.41×	13.63×	-3.74×	-96.0%	94.1%	-130.7%	-125.4%	-39.2%	-31.6%	-21.2%	0.16×	0.09×	-11.11×	6.64×	0.0%	2	2.76	2	—